Acrivon CFO awarded 132,925 stock options

Acrivon Therapeutics, Inc. reported that its Chief Financial Officer, Adam D. Levy, received a grant of stock options.

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. reported that its Chief Financial Officer, Adam D. Levy, received a grant of stock options. The award covers 132,925 options with an exercise price of $0.00 per share, characterized as a grant or award acquisition rather than an open-market purchase.

According to the vesting terms, 25% of the options vest on March 1, 2027, and the remaining options vest in 36 substantially equal monthly installments after that date. All vesting requires Mr. Levy to remain in continuous service with the company through each vesting date.

Insider Trade Summary

Grant/Award: 132,925 shares

Grant/Award 1 txn

Insider Levy Adam D.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	132,925	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 132,925 contracts (Direct)

Footnotes (1)

1. F1. Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ACRV report for CFO Adam D. Levy?

Acrivon Therapeutics reported that CFO Adam D. Levy received a grant of 132,925 stock options. These options were awarded at an exercise price of $0.00 per share as a compensatory grant, not through an open-market stock purchase.

How many stock options were granted to the ACRV CFO in this Form 4?

The CFO of Acrivon Therapeutics was granted 132,925 stock options. This entire amount is reported as a single derivative transaction, characterized as a grant or award acquisition with no purchase price per option listed in the filing.

What is the vesting schedule for the ACRV CFO’s new stock options?

The options vest 25% on March 1, 2027, with the remaining shares vesting in 36 substantially equal monthly installments. Each vesting date is conditioned on the CFO’s continuous service with Acrivon Therapeutics through that specific date.

Was the ACRV CFO’s Form 4 transaction a stock purchase or an award?

The transaction is reported as a grant or award acquisition of stock options, not an open-market stock purchase. The filing uses transaction code A, which indicates a grant, award, or other acquisition of derivative securities such as options.

What ownership type is reported for the ACRV CFO’s option grant?

The filing lists the ownership of the stock options as direct. This means the reported 132,925 options are directly attributed to the CFO, rather than being held through an indirect entity such as a trust, partnership, or family investment vehicle.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 04:19 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levy Adam D.

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.51	03/01/2026		A		132,925		(1)	02/29/2036	Common Stock	132,925	$0	132,925	D

Explanation of Responses:

1. Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.

	/s/ Adam D. Levy	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.